Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Tan Sheet

Executive Summary

FTC/Garden of Life case continues; FDA deems ForMor in violation of GMPs; Kanebo faulted for pharmaceutical GMP failures; CytoSport settles litigation over Muscle Milk labeling; USPlabs’ carb claim canned in NAD review; FDA extends comment time on FSMA tracking pilots.

Advertisement

Related Content

FTC Leaves Supplement Industry Still Waiting For Shift Away From RCT Standard For Claims
FTC Stretched Standards In Enforcement Against Bayer Probiotic Claim
FTC Stretched Standards In Enforcement Against Bayer Probiotic Claim
Claims Emerge To Join “Natural” As Class Action Fodder
Claims Emerge To Join “Natural” As Class Action Fodder
Garden Of Life, POM Wonderful Cases Help FTC Hone Decree Language
Garden Of Life, POM Wonderful Cases Help FTC Hone Decree Language
In Brief
In Brief
HIV/AIDS, Cancer Cure Supplement Claims Targeted In Six FTC Actions

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106355

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel